Danish pharma giant Novo Nordisk announced an expansive partnership with OpenAI on April 14, deploying OpenAI models across drug discovery, clinical trials, manufacturing, supply chains, and commercial operations. The Ozempic maker wants to cut the time from research to patient, especially as rival Eli Lilly eats into its lead in obesity treatments. OpenAI will also help upskill Novo's global workforce on AI. Pilot programs start across R&D, manufacturing, and commercial in the coming months, with full integration targeted by year end. Financial terms were not disclosed. The deal is structured with strict data protections, human oversight, and governance guardrails — a nod to the regulatory scrutiny that comes with putting large language models anywhere near drug discovery and patient data.